Announcements Trials
Browse Landscape

Phase

Phase 2 23Phase 3 11Phase 1 11Phase NA 6Phase 2/3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 35OTHER 32NIH 7OTHER_GOV 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 10Breast Neoplasms 9Central Nervous System Neoplasms 8Multiple Myeloma 7Lung Neoplasms 7Leukemia, Myeloid, Acute 6Ovarian Neoplasms 5Uterine Cervical Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Non-Hodgkin 4Leukemia 4Gliosarcoma 4Glioblastoma 4Burkitt Lymphoma 4Squamous Cell Carcinoma of Head and Neck 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Congenital Abnormalities 3Colorectal Neoplasms 3Stomach Neoplasms 2Small Cell Lung Carcinoma 2Recurrence 2Radiation Injuries 2Pancreatic Neoplasms 2Osteosarcoma 2Oligodendroglioma 2Neuroblastoma 2Myelodysplastic Syndromes 2Lymphoma 2Leukemia, Myelomonocytic, Acute 2Leukemia, Monocytic, Acute 2

Interventions

Paclitaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × NETWORK × Fallopian Tube Neoplasms × Clear all
NCT01402271 2023-12-11

Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

European Organisation for Research and Treatment of Cancer - EORTC

Phase 1/2 Completed
88 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡